Tadao Aikawa1, Noriko Oyama-Manabe2, Masanao Naya1, Hiroshi Ohira3, Ayako Sugimoto3, Ichizo Tsujino3, Masahiko Obara1, Osamu Manabe4, Kohsuke Kudo5, Hiroyuki Tsutsui6, Nagara Tamaki4. 1. Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. 2. Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan. norikooyama@med.hokudai.ac.jp. 3. First Department of Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. 4. Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. 5. Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Kita-14, Nishi-5, Kita-ku, Sapporo, 060-8648, Japan. 6. Department of Cardiovascular Medicine, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Abstract
OBJECTIVES: To evaluate the diagnostic value of delayed contrast-enhanced computed tomography (DE-CT) for cardiac sarcoidosis (CS) in patients with or without implantable devices, including a quantitative comparison with late gadolinium enhancement cardiac magnetic resonance (LGE-CMR). METHODS: Twenty-four patients (mean age, 64 ± 9 years; 17 women) with known or suspected CS underwent retrospective electrocardiogram-gated DE-CT at 80 kV with knowledge-based iterative model reconstruction. Fourteen patients without implantable devices also underwent LGE-CMR, while ten with pacemakers or implantable cardioverter-defibrillators did not. The presence of hyperenhanced myocardium was assessed visually and quantitatively using a 5-standard deviation threshold above the mean of remote myocardium. RESULTS: Inter-observer agreement for visual detection of hyperenhanced segments on DE-CT was excellent in patients with implantable devices and in those without (κ = 0.91 and κ = 0.94, respectively). Comparisons of the percent area of hyperenhanced myocardium between DE-CT and LGE-CMR on both per-patient and per-segment analyses showed good correlations (r = 0.96 and r = 0.83, respectively; p < 0.001). The sensitivity and specificity of DE-CT for the diagnosis of CS were 94% and 33%. CONCLUSIONS: The extent of hyperenhanced lesion with DE-CT showed good agreement with LGE-CMR results. DE-CT showed high sensitivity for detecting CS and may be useful particularly in patients with contraindications to CMR. KEY POINTS: • Delayed contrast-enhanced CT (DE-CT) can be applied to patients with implantable devices. • DE-CT can detect cardiac sarcoidosis (CS) lesions similarly to cardiac MRI. • DE-CT shows high sensitivity for detecting CS. • DE-CT may be useful particularly in patients with contraindications to cardiac MRI.
OBJECTIVES: To evaluate the diagnostic value of delayed contrast-enhanced computed tomography (DE-CT) for cardiac sarcoidosis (CS) in patients with or without implantable devices, including a quantitative comparison with late gadolinium enhancement cardiac magnetic resonance (LGE-CMR). METHODS: Twenty-four patients (mean age, 64 ± 9 years; 17 women) with known or suspected CS underwent retrospective electrocardiogram-gated DE-CT at 80 kV with knowledge-based iterative model reconstruction. Fourteen patients without implantable devices also underwent LGE-CMR, while ten with pacemakers or implantable cardioverter-defibrillators did not. The presence of hyperenhanced myocardium was assessed visually and quantitatively using a 5-standard deviation threshold above the mean of remote myocardium. RESULTS: Inter-observer agreement for visual detection of hyperenhanced segments on DE-CT was excellent in patients with implantable devices and in those without (κ = 0.91 and κ = 0.94, respectively). Comparisons of the percent area of hyperenhanced myocardium between DE-CT and LGE-CMR on both per-patient and per-segment analyses showed good correlations (r = 0.96 and r = 0.83, respectively; p < 0.001). The sensitivity and specificity of DE-CT for the diagnosis of CS were 94% and 33%. CONCLUSIONS: The extent of hyperenhanced lesion with DE-CT showed good agreement with LGE-CMR results. DE-CT showed high sensitivity for detecting CS and may be useful particularly in patients with contraindications to CMR. KEY POINTS: • Delayed contrast-enhanced CT (DE-CT) can be applied to patients with implantable devices. • DE-CT can detect cardiac sarcoidosis (CS) lesions similarly to cardiac MRI. • DE-CT shows high sensitivity for detecting CS. • DE-CT may be useful particularly in patients with contraindications to cardiac MRI.
Authors: Albert C Lardo; Marco A S Cordeiro; Caterina Silva; Luciano C Amado; Richard T George; Anastasios P Saliaris; Karl H Schuleri; Veronica R Fernandes; Menekhem Zviman; Saman Nazarian; Henry R Halperin; Katherine C Wu; Joshua M Hare; Joao A C Lima Journal: Circulation Date: 2006-01-24 Impact factor: 29.690
Authors: Hiroshi Ohira; David H Birnie; Elena Pena; Jordan Bernick; Brian Mc Ardle; Eugene Leung; George A Wells; Keiichiro Yoshinaga; Ichizo Tsujino; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Masaharu Nishimura; Nagara Tamaki; Alexander Dick; Carole Dennie; Ran Klein; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy; Benjamin J W Chow; Ross Davies; Renee Hessian; Peter Liu; Rob S B Beanlands; Pablo B Nery Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-11 Impact factor: 9.236
Authors: Koen Nieman; Michael D Shapiro; Maros Ferencik; Cesar H Nomura; Suhny Abbara; Udo Hoffmann; Herman K Gold; Ik-Kyung Jang; Thomas J Brady; Ricardo C Cury Journal: Radiology Date: 2008-04 Impact factor: 11.105
Authors: Ron Blankstein; Michael Osborne; Masanao Naya; Alfonso Waller; Chun K Kim; Venkatesh L Murthy; Pedram Kazemian; Raymond Y Kwong; Michifumi Tokuda; Hicham Skali; Robert Padera; Jon Hainer; William G Stevenson; Sharmila Dorbala; Marcelo F Di Carli Journal: J Am Coll Cardiol Date: 2013-10-16 Impact factor: 24.094
Authors: Ernesto Di Cesare; Scipione Carerj; Anna Palmisano; Maria Ludovica Carerj; Federica Catapano; Davide Vignale; Annamaria Di Cesare; Gianluca Milanese; Nicola Sverzellati; Marco Francone; Antonio Esposito Journal: Radiol Med Date: 2020-07-16 Impact factor: 3.469
Authors: Yan Yatsynovich; Damian Valencia; Mikhail Petrov; Juan David Linares; Mufti M Rahman; Nathaniel Dittoe Journal: Curr Treat Options Cardiovasc Med Date: 2018-08-07
Authors: Anna Palmisano; Davide Vignale; Giulia Benedetti; Alessandro Del Maschio; Francesco De Cobelli; Antonio Esposito Journal: Radiol Med Date: 2019-11-29 Impact factor: 3.469
Authors: Jagat Narula; Y Chandrashekhar; Amir Ahmadi; Suhny Abbara; Daniel S Berman; Ron Blankstein; Jonathon Leipsic; David Newby; Edward D Nicol; Koen Nieman; Leslee Shaw; Todd C Villines; Michelle Williams; Harvey S Hecht Journal: J Cardiovasc Comput Tomogr Date: 2020-11-20